{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:54:05Z","timestamp":1761512045165,"version":"3.32.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1992,11,1]],"date-time":"1992-11-01T00:00:00Z","timestamp":720576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1992,11,1]],"date-time":"1992-11-01T00:00:00Z","timestamp":720576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1992,11]]},"DOI":"10.1007\/bf00944192","type":"journal-article","created":{"date-parts":[[2005,1,7]],"date-time":"2005-01-07T11:58:46Z","timestamp":1105099126000},"page":"337-343","source":"Crossref","is-referenced-by-count":27,"title":["An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma"],"prefix":"10.1007","volume":"10","author":[{"given":"G.","family":"Falkson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C.","family":"Borden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. I.","family":"Falkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00944192_CR1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1988.6.3.527","volume":"6","author":"AS Alberts","year":"1988","unstructured":"Alberts AS, Falkson G, Goedhals L, Vorobiof DA, van der Merwe CA: Malignant Pleural Mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527\u2013535, 1988","journal-title":"J Clin Oncol"},{"key":"BF00944192_CR2","first-page":"391","volume":"22","author":"H W\u00f6rn","year":"1974","unstructured":"W\u00f6rn H: M\u00f6glichkeiten und ergebnisse der chirurgischen behandlung des malignen pleuramesothelioms. Thoraxchirurgie 22:391\u2013393, 1974","journal-title":"Thoraxchirurgie"},{"key":"BF00944192_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thx.31.1.15","volume":"31","author":"EG Butchart","year":"1976","unstructured":"Butchart EG, Ashcroft T, Barnsley WC, Holden MP: Pleuroopneumocectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31:15\u201324, 1976","journal-title":"Thorax"},{"key":"BF00944192_CR4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0003-4975(10)64593-6","volume":"42","author":"MJ DaVille","year":"1986","unstructured":"DaVille MJ, Faber LP, Kittle CF, Jensik RJ: Extrapleural pneumonectomy for diffuse malignant mesothelioma. Ann Thorac Surg 42:612\u2013618, 1986","journal-title":"Ann Thorac Surg"},{"key":"BF00944192_CR5","first-page":"3785","volume":"26","author":"GA DeLaria","year":"1986","unstructured":"DeLaria GA, Jensik R, Faber LP, Kittle CF: Surgical management of malignant mesothelioma. Ann Thorac Surg 26:3785\u2013382, 1986","journal-title":"Ann Thorac Surg"},{"issue":"Suppl","key":"BF00944192_CR6","first-page":"A83","volume":"4","author":"V Rusch","year":"1988","unstructured":"Rusch V, Holmes EC (For the Lung cancer study group [LCSG]): Extra-pleural pneumocectomy (EPP) for malignant mesothelioma. Lung Cancer 4 (Suppl):A83 (Abst 5.16), 1988","journal-title":"Lung Cancer"},{"key":"BF00944192_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/thx.39.4.255","volume":"39","author":"MR Law","year":"1984","unstructured":"Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M: Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39:255\u2013259, 1984","journal-title":"Thorax"},{"key":"BF00944192_CR8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N","volume":"35","author":"N Martini","year":"1975","unstructured":"Martini N, Bains M, Beattie EJ: Indications for pleurectomy in malignant effusion. Cancer 35:734\u2013738, 1975","journal-title":"Cancer"},{"key":"BF00944192_CR9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00000421-199002000-00002","volume":"13","author":"DL Ball","year":"1990","unstructured":"Ball DL, Cruickshank DG: The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol (CCT) 13:4\u20139, 1990","journal-title":"Am J Clin Oncol (CCT)"},{"key":"BF00944192_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0305-7372(88)90023-0","volume":"15","author":"G Falkson","year":"1988","unstructured":"Falkson G, Alberts AS, Falkson HC: Malignant pleural mesothelioma treatment: the current state of the art. Cancer Treat Rev 15:231\u2013242, 1988","journal-title":"Cancer Treat Rev"},{"key":"BF00944192_CR11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B","volume":"54","author":"VJ Harvey","year":"1984","unstructured":"Harvey VJ, Slevin ML, Ponder BAJ, Blackshaw AJ, Wrigley PFM: Chemotherapy of diffuse malignant mesothelioma: Phase II trials of single agent 5-fluorouracil and adriamycin. Cancer 54:961\u2013964, 1984","journal-title":"Cancer"},{"key":"BF00944192_CR12","first-page":"1431","volume":"69","author":"PG Sorenson","year":"1985","unstructured":"Sorenson PG, Bach F, Bork E, Hansen HH: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431\u20131432, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00944192_CR13","first-page":"711","volume":"69","author":"DM Mintzer","year":"1985","unstructured":"Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711\u2013712, 1985","journal-title":"Cancer Treat Rep"},{"key":"BF00944192_CR14","first-page":"821","volume":"67","author":"D Kelsen","year":"1983","unstructured":"Kelsen D, Gralla R, Cheng E, Martini N: Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treat Rep 67:821\u2013822, 1983","journal-title":"Cancer Treat Rep"},{"key":"BF00944192_CR15","first-page":"1029","volume":"70","author":"EA Eisenhauer","year":"1986","unstructured":"Eisenhauer EA, Evans WK, Raghaven D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS: Phase II study of mitoxantrone in patients with mesothelioma. A National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 70:1029\u20131030, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00944192_CR16","first-page":"1335","volume":"70","author":"BMJ Cantwell","year":"1986","unstructured":"Cantwell BMJ, Earnshaw M, Harris AL: Phase II study of a novel antifolate n10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 70:1335\u20131336, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00944192_CR17","doi-asserted-by":"crossref","unstructured":"Gatzemeier U, Calavrezos A, Kaukel E, Koschel G, Maghussen H, Radenbach D: The new anthracycline THP- ADM (4\u2032-0-tetrahydropyrnyl-adriamycin) in the treatment of malignant pleural mesothelioma. Presented at the 18th National Cancer Congress of the German Cancer Society, 1986. J Cancer Res Clin Oncol 111 (Suppl) 6: 1986. (Abstract)","DOI":"10.1007\/BF02580035"},{"key":"BF00944192_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00194548","volume":"9","author":"HM Dhingra","year":"1991","unstructured":"Dhingra HM, Murphy WK, Winn RJ, Raber MN, Hong WH: Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma. Invest New Drugs 9:69\u201372, 1991","journal-title":"Invest New Drugs"},{"key":"BF00944192_CR19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/0277-5379(91)90430-L","volume":"27","author":"FJM van Breukelen","year":"1991","unstructured":"van Breukelen FJM, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A, Dalesio O: Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27:1627\u20131629, 1991.","journal-title":"Eur J Cancer"},{"key":"BF00944192_CR20","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P","volume":"52","author":"IIJ Lerner","year":"1983","unstructured":"Lerner IIJ, Schoenfeld DA, Martin A, Falkson G, Borden E: Malignant mesothelioma: The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981\u20131985, 1983","journal-title":"Cancer"},{"key":"BF00944192_CR21","first-page":"921","volume":"32","author":"JJ van Dyk","year":"1972","unstructured":"van Dyk JJ, Falkson HC, van der Merwe AM, Falkson G: Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32:921\u2013924, 1972","journal-title":"Cancer Res"},{"key":"BF00944192_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00265383","volume":"9","author":"G Falkson","year":"1982","unstructured":"Falkson G, van Dyk JJ, Stapelberg R, Falkson HC: Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmacol 9:81\u201384, 1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00944192_CR23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/80.9.698-a","volume":"80","author":"AS Alberts","year":"1988","unstructured":"Alberts AS, Falkson G, van Zyl L: Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. (Letter) Jnl Nat Cancer Inst 80:698\u2013700, 1988","journal-title":"Jnl Nat Cancer Inst"},{"key":"BF00944192_CR24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech LH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649\u2013655, 1982","journal-title":"Am J Clin Oncol (CCT)"},{"key":"BF00944192_CR25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"58","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Non parametric estimation from incomplete observations. Journal of the Am Stat Assoc 58:457\u2013481, 1958","journal-title":"Journal of the Am Stat Assoc"},{"key":"BF00944192_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2344317","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto R, Peto J: Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society, Series A 135:185\u2013198, 1972","journal-title":"Journal of the Royal Statistical Society, Series A"},{"key":"BF00944192_CR27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR: Regression models and life tables (with discussion) Journal of the Royal Stat Soc, Series B, 34:187\u2013220, 1972.","journal-title":"Journal of the Royal Stat Soc, Series B"},{"key":"BF00944192_CR28","first-page":"350","volume":"10","author":"B Zidar","year":"1991","unstructured":"Zidar B, Metch B, Militello L, Balcerzak S, Pierce H: A Phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group (SWOG) study. Amer Soc Clin Oncol 10:350, 1991 (Abstract #1245)","journal-title":"Amer Soc Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00944192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00944192\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00944192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00944192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T12:14:45Z","timestamp":1734869685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00944192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1992,11]]}},"alternative-id":["BF00944192"],"URL":"https:\/\/doi.org\/10.1007\/bf00944192","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[1992,11]]}}}